摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-(trifluoromethyl)benzo[b]thiophene | 120568-07-2

中文名称
——
中文别名
——
英文名称
7-(trifluoromethyl)benzo[b]thiophene
英文别名
7-(trifluoromethyl)-1-benzothiophene
7-(trifluoromethyl)benzo[b]thiophene化学式
CAS
120568-07-2
化学式
C9H5F3S
mdl
——
分子量
202.2
InChiKey
ZIMDUVYFMGCYAB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    232.3±35.0 °C(Predicted)
  • 密度:
    1.379±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    28.2
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • Cathodic C–H Trifluoromethylation of Arenes and Heteroarenes Enabled by an in Situ-Generated Triflyltriethylammonium Complex
    作者:Wolfgang Jud、Snjezana Maljuric、C. Oliver Kappe、David Cantillo
    DOI:10.1021/acs.orglett.9b02948
    日期:2019.10.4
    While several trifluoromethylation reactions involving the electrochemical generation of CF3 radicals via anodic oxidation have been reported, the alternative cathodic, reductive radical generation has remained elusive. Herein, the first cathodic trifluoromethylation of arenes and heteroarenes is reported. The method is based on the electrochemical reduction of an unstable triflyltriethylammonium complex
    尽管已经报道了一些涉及通过阳极氧化电化学生成CF3自由基的三氟甲基化反应,但替代性的阴极,还原自由基的生成仍然难以捉摸。在此,报道了芳烃和杂芳烃的第一次阴极三氟甲基化。该方法基于电化学还原由廉价的三氟氯甲烷和三乙胺就地生成的不稳定的三氟三乙铵络合物,该络合物产生CF3自由基,这些自由基被芳烃捕获在阴极表面上。
  • Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
    申请人:Buck A. Elizabeth
    公开号:US20070280928A1
    公开(公告)日:2007-12-06
    The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA®).
    本发明提供了一种治疗患者体内NSCL、胰腺、结肠或乳腺癌肿瘤或肿瘤转移的方法,包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合,其中该药物是mTOR抑制剂,可以附加其他药物或治疗,如其他抗癌药物或放射治疗。本发明还提供了一种治疗患者体内肿瘤或肿瘤转移的方法,包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合,其中该药物是一种能够结合并直接抑制mTORC1和mTORC2激酶的mTOR抑制剂。本发明还提供了一种制药组合物,包括一种能够结合并直接抑制mTORC1和mTORC2激酶的EGFR激酶抑制剂和mTOR抑制剂,以及一种药用载体。本发明中可用于实施该方法的EGFR激酶抑制剂的首选示例是化合物厄洛替尼盐酸盐(也称为TARCEVA®)。
  • NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS
    申请人:Oncostellae, S.L.
    公开号:EP3480201A1
    公开(公告)日:2019-05-08
    The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and/or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.
    本发明涉及一种新型的二氢吡啶衍生物,其化学式为(I):作为选择的核受体调节剂,所述核受体包括雄激素受体和糖皮质激素受体,以及其制备方法,包括所述化合物的制药组合物和利用所述化合物制造用于治疗可以通过调节雄激素受体和/或糖皮质激素受体改善的病理情况或疾病的药物,所述病理情况或疾病包括癌症、转移性癌症、良性前列腺增生、多囊卵巢综合征(PCOS)、脱发、多毛症、痤疮、性腺功能减退、肌肉消耗性疾病、虚弱、库欣综合征、抗精神病药物诱导的体重增加、肥胖、创伤后应激障碍和酗酒。
  • Trifluoromethylation of aromatic compounds with bis(trifluoroacetyl) peroxide
    作者:Hideo Sawada、Masaharu Nakayama、Masato Yoshida、Tatsuro Yoshida、Nobumasa Kamigata
    DOI:10.1016/s0022-1139(00)82927-9
    日期:1990.3
    Bis(trifluoroacety) peroxide was found to be thermally stable, and trifluoromenthylation of aromatic compounds was studied using this peroxide. Thrifluoromethylation of electron-rich benzenes, furan, thiophene, or their benzo derivatives proceeded with the peroxide in moderate to high yields.
    发现双(三氟乙氧基)过氧化物是热稳定的,并且使用该过氧化物研究了芳族化合物的三氟乙酰化。富电子的苯,呋喃,噻吩或其苯并衍生物的三氟甲基化与过氧化物一起以中等至高收率进行。
  • Photochemical Trifluoromethylation of Some Aromatic and Heteroaromatic Compounds with Trifluoromethyl Bromide
    作者:Takeo Akiyama、Kohji Kato、Masatsugu Kajitani、Yoshio Sakaguchi、Junko Nakamura、Hisaharu Hayashi、Akira Sugimori
    DOI:10.1246/bcsj.61.3531
    日期:1988.10
    The photochemical introduction of trifluoromethyl group with CF3Br in aromatic and heteroaromatic rings was investigated for 9 compounds. Naphthalene, anthracene, anisole, N,N-dimethylaniline, ferrocene, benzo[b]thiophene, isoquinoline, and N-methylpyrrole gave trifluoromethylated products in 6.5–100% yields. In one step from uracil, a pharmacologically important 5-trifluoromethyluracil can be synthesized
    研究了 9 种化合物在芳环和杂芳环中三氟甲基与 CF3Br 的光化学引入。萘、蒽、苯甲醚、N,N-二甲基苯胺、二茂铁、苯并[b]噻吩、异喹啉和 N-甲基吡咯以 6.5-100% 的产率得到三氟甲基化产物。在尿嘧啶的一个步骤中,一种药理学上重要的 5-三氟甲基尿嘧啶可以通过这种方法以 11% 的产率合成。根据对萘-CF3Br-CH3CN 系统进行的机理研究,发现反应是通过电子从萘的激发单线态转移到 CF3Br 进行的。
查看更多

同类化合物